Morgan Stanley Maintains Overweight on Elevance Health, Lowers Price Target to $316

Benzinga · 07/18 11:32
Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $428 to $316.